Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2007 1
2012 2
2014 1
2015 1
2016 2
2017 2
2018 3
2019 4
2020 1
2021 2
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
[Fertility preservation in oncology].
Chaput L, Grémeau AS, Vorilhon S, Pons H, Chabrot C, Grèze V, Pouly JL, Brugnon F. Chaput L, et al. Among authors: chabrot c. Bull Cancer. 2018 Jan;105(1):99-110. doi: 10.1016/j.bulcan.2017.11.001. Epub 2017 Dec 6. Bull Cancer. 2018. PMID: 29221621 Review. French.
Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study.
Chevallier P, Robillard N, Charbonnier A, Raffoux E, Maury S, Carras S, Chabrot C, Fohrer C, Bernard M, Blade JS, Etienne A, Talmant P, Delaunay J, Guillaume T, Mohty M, Bene MC, Ifrah N, Dombret H. Chevallier P, et al. Among authors: chabrot c. Blood. 2012 Mar 15;119(11):2474-7. doi: 10.1182/blood-2011-11-390781. Epub 2012 Jan 20. Blood. 2012. PMID: 22267607 Free article. Clinical Trial.
Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML.
Alleg M, Solis M, Baloglu S, Cotton F, Kerschen P, Bourre B, Ahle G, Pruvo JP, Leclerc X, Vermersch P, Papeix C, Maillart É, Houillier C, Chabrot CM, Claise B, Malak S, Martin-Blondel G, Bonneville F, Caulier A, Marolleau JP, Bonnefoy JT, Agape P, Kennel C, Roussel X, Chauchet A, De Seze J, Fafi-Kremer S, Kremer S. Alleg M, et al. Among authors: chabrot cm. Eur Radiol. 2021 May;31(5):2944-2955. doi: 10.1007/s00330-020-07362-y. Epub 2020 Nov 6. Eur Radiol. 2021. PMID: 33155106 Free PMC article.
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.
Gressin R, Daguindau N, Tempescul A, Moreau A, Carras S, Tchernonog E, Schmitt A, Houot R, Dartigeas C, Pignon JM, Corm S, Banos A, Mounier C, Dupuis J, Macro M, Fleury J, Jardin F, Sarkozy C, Damaj G, Feugier P, Fornecker LM, Chabrot C, Dorvaux V, Bouadallah K, Amorin S, Garidi R, Voillat L, Joly B, Celigny PS, Morineau N, Moles MP, Zerazhi H, Fontan J, Arkam Y, Alexis M, Delwail V, Vilque JP, Ysebaert L, Le Gouill S, Callanan MB; Lymphoma Study Association. Gressin R, et al. Among authors: chabrot c. Haematologica. 2019 Jan;104(1):138-146. doi: 10.3324/haematol.2018.191429. Epub 2018 Aug 31. Haematologica. 2019. PMID: 30171024 Free PMC article. Clinical Trial.
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Carras S, Torroja A, Emadali A, Montaut E, Daguindau N, Tempescul A, Moreau A, Tchernonog E, Schmitt A, Houot R, Dartigeas C, Barbieux S, Corm S, Banos A, Fouillet L, Dupuis J, Macro M, Fleury J, Jardin F, Sarkozy C, Damaj G, Feugier P, Fornecker LM, Chabrot C, Dorvaux V, Bouabdallah K, Amorim S, Garidi R, Voillat L, Joly B, Morineau N, Moles MP, Zerazhi H, Fontan J, Arkam Y, Alexis M, Delwail V, Vilque JP, Ysebaert L, Burroni B, Callanan M, Le Gouill S, Gressin R. Carras S, et al. Among authors: chabrot c. Haematologica. 2024 Jun 1;109(6):1857-1865. doi: 10.3324/haematol.2023.283724. Haematologica. 2024. PMID: 38031755 Free PMC article. Clinical Trial.
A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study.
Labreche K, Daniau M, Sud A, Law PJ, Royer-Perron L, Holroyd A, Broderick P, Went M, Benazra M, Ahle G, Soubeyran P, Taillandier L, Chinot OL, Casasnovas O, Bay JO, Jardin F, Oberic L, Fabbro M, Damaj G, Brion A, Mokhtari K, Philippe C, Sanson M, Houillier C, Soussain C, Hoang-Xuan K, Houlston RS, Alentorn A; LOC Network. Labreche K, et al. Neuro Oncol. 2019 Aug 5;21(8):1039-1048. doi: 10.1093/neuonc/noz088. Neuro Oncol. 2019. PMID: 31102405 Free PMC article.
16 results